Ignite Creation Date:
2025-12-24 @ 7:50 PM
Ignite Modification Date:
2026-03-09 @ 4:09 AM
Study NCT ID:
NCT01678404
Status:
UNKNOWN
Last Update Posted:
2012-09-05
First Post:
2012-09-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
Sponsor:
Korea Cancer Center Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
MZL 131I-rituximab RIT
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None